March 2021 marks the end of CCADD's advisory to Idience's new molecule research.

Idience Co., LTD., a subsidiary of Ildong Pharmaceutical Co.,Ltd. (a major pharmaceutical company in Korea), is a No-Research-Development-Only (NRDO) company that focuses on developing and commercializing novel oncology drugs. 

Particularly, IDX-1197, a potent poly (ADP-ribose) polymerase (PARP) inhibitors that causes synthetic lethality in cancer cells, has received the spotlight not only from the researchers, but from the investigators. Idience has successfully filed an investigational new drug (IND) for IDX-1197 to the U.S. Food and Drug Administration (FDA) last year. If approved and marketed, IDX-1197 will be used as monotherapy or an add-on to other anti-cancer agents targeting multiple solid tumors.

CCADD played a key role in speeding up the clinical development process of IDX-1197. From January to March 2021, CCADD analyzed preclinical and clinical data on other PARP inhibitors already developed or under development. Besides, CCADD comprehensively reviewed the results of completed, ongoing, or planned studies of IDX-1197, and compared the results with those of other PARP inhibitors such as Olaparib, Rucaparib, Niraparib, and Talazoparib. The analysis laid the foundation for how CCADD could help Idience better navigate the complex drug development process. This consulting project was led by Siun Kim, Yesol Hong, and Jung-Hyun Won under the auspice of Prof. Howard Lee.

On balance, it was a great experience to have worked with Idience on this project, and CCADD gives its best wishes to Idience for a successful global clinical development of IDX-1197 in the near future.